Please Note: This trial is no longer enrolling new participants
Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)
| Protocol No. | CTO-IRB00306149 | Scope | National |
|---|---|---|---|
| Principal Investigator | Greg Durm | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
